Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, Prospective, Randomized, Double-blind, Parallel-group, Phase III.

Trial Profile

Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, Prospective, Randomized, Double-blind, Parallel-group, Phase III.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Pantoprazole (Primary) ; Esomeprazole
  • Indications Erosive oesophagitis; Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 21 May 2013 Results presented at Digestive Disease Week 2013.
    • 25 Jun 2012 Actual patient number is 713 according to ClinicalTrials.gov.
    • 25 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top